Psoriatic arthritis is a chronic inflammatory joint disease closely related to psoriasis. This condition primarily affects the joints and skin, leading to pain, swelling, and functional impairment. It has a characteristic pattern of recurrent flare-ups, which may have a long-term impact on the quality of life of patients.
The disease is characterized by an abnormally active immune system that triggers a chronic inflammatory response in the joint synovium. Unlike other autoimmune diseases, psoriatic arthritis often occurs simultaneously with or follows skin lesions of psoriasis. According to epidemiological studies, about 30% of psoriasis patients eventually develop joint symptoms.
The pathogenesis of psoriatic arthritis involves a complex interplay of genetic, immune abnormalities, and environmental triggers. Studies show that specific gene polymorphisms, such as HLA-B27, increase the risk of developing the disease, but a single gene mutation is not a decisive factor. The overactivation of T cells and cytokines (such as IL-17, TNF-α) in the immune system leads to persistent inflammatory responses in joint tissues.
The main risk factors include:
Clinical manifestations vary widely, with typical symptoms including symmetrical or asymmetrical joint pain and swelling, commonly affecting the distal joints (such as dactylitis) and the spine. Patients often describe morning stiffness that gradually improves with activity. Specific symptoms such as nail pitting and pain at tendon attachment sites (such as Achilles tendinopathy) are also important diagnostic clues.
Based on the pattern of joint involvement, it can be classified into five subtypes:
Diagnosis requires integration of clinical assessment, imaging studies, and laboratory data. Physicians will inquire in detail about the history of psoriasis and family history, and conduct joint examinations to look for specific signs, such as pustular nail lesions or tenderness at tendon attachment sites. Imaging studies are a key step; X-rays may show joint calcification or bone erosion, while MRI can detect inflammatory signs earlier.
Blood tests, although not directly diagnostic, are used to rule out other types of arthritis such as rheumatoid factor or anti-CCP antibodies. The CASPAR diagnostic criteria established in 2015 require fulfillment of three of the following conditions:
It is necessary to differentiate from rheumatoid arthritis, gout, and ankylosing spondylitis. In psoriatic arthritis patients, rheumatoid factor is often negative, while the positive rate of HLA-B27 in spondylitic patients is about 50%, which aids in differential diagnosis.
The treatment goal is to control inflammation, relieve symptoms, and prevent joint destruction. Treatment plans are categorized into basic therapy and aggressive therapy based on the severity of the condition. Non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) are commonly used basic medications, but they have limited effects on inflammatory arthritis.
The application of biologics has fundamentally changed the treatment paradigm; anti-TNF-α drugs (such as infliximab) can directly inhibit inflammatory pathways. New oral JAK inhibitors provide non-injection treatment options. Surgical treatment is reserved for patients with severe joint damage, and joint replacement surgery can restore function.
Treatment plans should be selected based on subtype: spondylitic type may require NSAIDs combined with biologics, while destructive type needs early use of aggressive medications. Regular monitoring of treatment response and adjustment of medication dosage according to ACR/EULAR treatment guidelines is essential.
Although complete prevention is not possible, active management can delay progression. Controlling skin lesions of psoriasis can reduce the risk of joint involvement; the use of topical steroids or phototherapy can decrease skin inflammation. Regular exercise can maintain joint flexibility, and low-impact activities such as swimming are more friendly to patients.
Quitting smoking has been shown to reduce the risk of developing the disease, as chemicals in tobacco can promote inflammatory responses. Regular skin examinations can detect lesions early, and it is recommended to conduct joint function assessments every 6-12 months.
You should seek medical attention immediately if the following occurs: persistent joint swelling for more than 3 weeks, morning stiffness lasting more than half an hour, or new erythema with scaling on the skin. If diagnosed patients experience worsening symptoms, drug side effects, or functional impairment, they need to return to the hospital for evaluation.
Early diagnosis is crucial, as delayed treatment may lead to irreversible joint damage. It is recommended that when symptoms are suspected, patients should consult a physician specializing in rheumatologic and immunological diseases for a complete evaluation.
The effectiveness of treatment should be observed through joint swelling, pain levels, and changes in skin lesions. Physicians typically track progress through clinical assessments, blood inflammatory markers (such as CRP, ESR), and imaging studies. If symptoms do not significantly improve within 3-6 months, it may be necessary to adjust the type or dosage of medication.
What measures can be taken in daily life to alleviate symptoms?Regular low-impact exercises (such as swimming, yoga) can enhance joint flexibility. Controlling body weight can reduce the burden on lower limb joints, and quitting smoking and avoiding cold exposure to joints are also common recommendations. Patients should avoid maintaining the same posture for extended periods and use assistive devices for daily activities.
How does psoriatic arthritis differ from general arthritis in terms of joint damage?This disease often affects the distal interphalangeal joints (fingertips) and may be accompanied by nail pitting or skin erythema. Unlike rheumatoid arthritis, bone destruction is often symmetrical, but the proportion of spinal involvement is lower. Early treatment can reduce the risk of irreversible joint deformities.
Are there issues with antibody resistance in biologic treatments?About 5-15% of patients may experience reduced efficacy due to drug resistance, especially when using TNF-α inhibitors. Physicians will adjust the dosing interval based on drug concentration and antibody formation in the blood or switch to different mechanism drugs (such as IL-17/23 inhibitors). Regular monitoring is key.
How significant is the impact of psychological stress on the condition?Stress may trigger or exacerbate immune system activation; studies show that long-term stress increases inflammatory markers and the risk of symptom flares. It is recommended to relieve stress through mindfulness meditation, art therapy, or support groups, and psychological counseling can also help cope with the psychological impact of chronic illness.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
